Process analysis of variables for standardization of antifungal susceptibility testing of nonfermentative yeasts

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1563-1570

  Zaragoza, Oscar ^a   Mesa Arango, Ana C ^a,b   Gómez López, Alicia ^a   Bernal Martínez, Leticia ^a   Rodríguez Tudela, Juan Luis ^a   Cuenca Estrella, Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b UNIVERSIDAD DE ANTIOQUIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM SULFATE; AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; GLUCOSE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CRYPTOCOCCUS ALBIDUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; FUNGUS GROWTH; FUNGUS ISOLATION; GEOTRICHUM; GROWTH RATE; INOCULATION; KINETICS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; RHODOTORULA; STANDARDIZATION; TEMPERATURE; TRICHOSPORON; YARROWIA LIPOLYTICA; YEAST;

ANTIFUNGAL AGENTS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; GEOTRICHUM; MICROBIAL SENSITIVITY TESTS; RHODOTORULA; TRICHOSPORON; YARROWIA;

EID: 79953168059     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01631-10     Document Type: Article

References (23)

1. Byrnes, E. J., et al. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6:e1000850.
2. Casadevall, A., and J. R. Perfect. 1998. Cryptococcus neoformans. ASM Press, Washington, DC.
3. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard, 2nd ed. M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Cuenca-Estrella, M., et al. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
6. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. (Pubitemid 37222342)
7. Fera, M. T., E. La Camera, and A. De Sarro. 2009. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev. Anti Infect. Ther. 7:981-998.
8. Galanis, E., L. Hoang, P. Kibsey, M. Morshed, and P. Phillips. 2009. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: lessons learned from British Columbia. Can. J. Infect. Dis. Med. Microbiol. 20:23-28.
9. Ghannoum, M. A., et al. 1992. Susceptibility testing of Cryptococcus neoformans: a microdilution technique. J. Clin. Microbiol. 30:2881-2886.
10. Gomez-Lopez, A., O. Zaragoza, J. L. Rodriguez-Tudela, and M. Cuenca-Estrella. 2008. Pharmacotherapy of yeast infections. Expert Opin. Pharmacother. 9:2801-2816.
11. Hoang, L. M., J. A. Maguire, P. Doyle, M. Fyfe, and D. L. Roscoe. 2004. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J. Med. Microbiol. 53:935-940.
12. Kerkering, T. M., R. J. Duma, and S. Shadomy. 1981. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann. Intern. Med. 94:611-616.
13. Kurtzman, C. P., and J. W. Fell. 1998. The yeasts. A taxonomic study. Elsevier Science BV, Amsterdam, Netherlands.
14. Paphitou, N. I., et al. 2002. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob. Agents Chemother. 46:1144-1146.
15. Rodriguez-Tudela, J. L., et al. 2005. Susceptibility patterns and molecular identification of Trichosporon species. Antimicrob. Agents Chemother. 49: 4026-4034.
16. Rodriguez-Tudela, J. L., et al. 2000. Influence of shaking on antifungal susceptibility testing of Cryptococcus neoformans: a comparison of the NCCLS standard M27A medium, buffered yeast nitrogen base, and RPMI-2% glucose. Antimicrob. Agents Chemother. 44:400-404.
17. SPSS, Inc. 2009. Statistical analysis and advanced statistical analysis. SPSS, Inc., Chicago, IL.
18. St. Germain, G., and C. Dion. 1996. Effect of media on growth rate and susceptibility testing of Cryptococcus neoformans. Mycoses 39:201-206. (Pubitemid 26319926)
19. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
20. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
21. Subcommittee on Antifungal Susceptibility Testing of the ESCMID European Committee for Antimicrobial Susceptibility Testing. 2008. EUCAST technical note on voriconazole. Clin. Microbiol. Infect. 14:985-987.
22. Sugar, A. M. 1991. Cryptococcosis in the patient with AIDS. Mycopathologia 114:153-157.
23. White, T. J., T. Bruns, S. Lee, and J. Taylor. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p. 315-322. In G. H. Gelfand, J. J. Sninsky, T. J. White, and M. A. Innis (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.